Cargando…
First person – Jelmer Hoeksma
First Person is a series of interviews with the first authors of a selection of papers published in Disease Models & Mechanisms, helping early-career researchers promote themselves alongside their papers. Jelmer Hoeksma is first author on ‘Cercosporamide inhibits bone morphogenetic protein recep...
Formato: | Online Artículo Texto |
---|---|
Lenguaje: | English |
Publicado: |
The Company of Biologists Ltd
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522029/ http://dx.doi.org/10.1242/dmm.047282 |
_version_ | 1783588094123966464 |
---|---|
collection | PubMed |
description | First Person is a series of interviews with the first authors of a selection of papers published in Disease Models & Mechanisms, helping early-career researchers promote themselves alongside their papers. Jelmer Hoeksma is first author on ‘Cercosporamide inhibits bone morphogenetic protein receptor type I kinase activity in zebrafish’, published in DMM. Jelmer is a PhD student/technician in the lab of Jeroen den Hertog at Hubrecht Institute, Utrecht, The Netherlands, identifying biologically active fungal compounds and uncovering their mode of action in vivo. |
format | Online Article Text |
id | pubmed-7522029 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2020 |
publisher | The Company of Biologists Ltd |
record_format | MEDLINE/PubMed |
spelling | pubmed-75220292020-09-29 First person – Jelmer Hoeksma Dis Model Mech First Person First Person is a series of interviews with the first authors of a selection of papers published in Disease Models & Mechanisms, helping early-career researchers promote themselves alongside their papers. Jelmer Hoeksma is first author on ‘Cercosporamide inhibits bone morphogenetic protein receptor type I kinase activity in zebrafish’, published in DMM. Jelmer is a PhD student/technician in the lab of Jeroen den Hertog at Hubrecht Institute, Utrecht, The Netherlands, identifying biologically active fungal compounds and uncovering their mode of action in vivo. The Company of Biologists Ltd 2020-09-24 /pmc/articles/PMC7522029/ http://dx.doi.org/10.1242/dmm.047282 Text en © 2020. Published by The Company of Biologists Ltd http://creativecommons.org/licenses/by/4.0This is an Open Access article distributed under the terms of the Creative Commons Attribution License (https://creativecommons.org/licenses/by/4.0), which permits unrestricted use, distribution and reproduction in any medium provided that the original work is properly attributed. |
spellingShingle | First Person First person – Jelmer Hoeksma |
title | First person – Jelmer Hoeksma |
title_full | First person – Jelmer Hoeksma |
title_fullStr | First person – Jelmer Hoeksma |
title_full_unstemmed | First person – Jelmer Hoeksma |
title_short | First person – Jelmer Hoeksma |
title_sort | first person – jelmer hoeksma |
topic | First Person |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7522029/ http://dx.doi.org/10.1242/dmm.047282 |